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Abstract The myb gene family has three members, c-myb, 
A-myb, and B-myb. A-myb mRNA is mainly expressed in testis 
and peripheral blood leukocytes. A-Myb can activate transcrip- 
tion from the promoter containing Myb-binding sites in all cells 
examined. In addition to the two domains (a DNA-binding 
domain and a transcriptional activation domain), two negative 
regulatory domains have been identified in A-Myb. These results 
indicate that A-Myb functions as a transcriptional activator 
mainly in testis and peripheral blood cells, and the regulatory 
mechanism of A-Myb activity is similar to that of c-Myb. 
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1. Introduction 
The myb gene was originally identified as a transforming 
oncogene of avian myeloblastosis virus and E26 leukemia virus 
[20,34]. The c-myb proto-oncogene, the cellular homolog of 
v-myb. is essential for the proliferation of hematopoietic pro- 
genitor cells. The level of c-myb expression is predominantly, 
although not exclusively, high in immature hematopoietic cells, 
and its expression is turned off during terminal differentiation 
[8,16,43]. Constitutive expression of introduced c-myb blocks 
the induced differentiation of immature erythroid cells [5,41], 
and treatment with an antisense oligonucleotide directed to 
c-myb blocks the proliferation of hematopoietic precursor cells 
[13]. Furthermore, homozygous c-myb mutant mice are severly 
anemic and die in utero due to defective fetal hematopoiesis 
[25]. In addition to the role in hematopoietic progenitor cells, 
c-myb is also important in the mitogen-induced proliferation of 
T lymphocytes and smooth muscle cells. c-myb expression is 
induced after mitogenic stimulation of both T lymphocytes and 
smooth muscle cells, in parallel to entry into the S phase [4,38]. 
Inhibition of c-myb function by a dominant negative form or 
antisense oligonucleotide blocks thymopoiesis or proliferation 
of carotid arterial smooth muscle cells [1,36]. 
The c-myb gene product (c-Myb) is a transcriptional activa- 
tor that can bind to specific DNA sequences, AACNGN(A/T/ 
C) [2,39,45]. Both artificial promoter constructs containing 
Myb-binding sites [26,30,44] and the natural promoters of mim- 
1 and c-myb genes [9,27,29,46] are activated by c-Myb. c-Myb 
has three functional domains, responsible for DNA binding, 
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transcriptional activation, and negative regulation, respectively 
[35]. The negative regulatory domain (NRD), located in the 
carboxyl-proximal portion of the molecule, is important for 
modulation of c-Myb activity. Deletion of this domain in- 
creases both transactivating and transforming capacities, im- 
plying that this domain normally represses c-Myb activity 
[17,35]. A leucine zipper motif is in this NRD, and its disruption 
also markedly increases c-Myb activity [18]. Since the leucine 
zipper motif is well known to mediate dimerization of several 
DNA-binding proteins, these observations suggest that an in- 
hibitor binds to c-Myb through this leucine zipper. 
We isolated two c-myb-related genes, A-myb and B-myh, 
from human DNA libraries by cross-hybridization with a 
c-myb DNA probe [31]. In contrast to the restricted expression 
of c-myb mainly in the immature hematopoietic cells, their 
expression is not restricted to the hematopoietic system [31]. 
Expression of both c-myb and B-myb are growth-regulated, and 
increase in the G, period of cell cylcle, reaching a peak at the 
GJS boundary [14,33]. In contrast, A-myh is expressed in rest- 
ing T cells, and its levels gradually decrease after mitogenic 
stimulation [ 141. These facts suggest that the physiological role 
of A-myb is distinct from that of c-mvb and B-myb. Both 
A-Myb and B-Myb show extensive homology to c-Myb in three 
regions (the DNA-binding domain, the carboxyl-terminal half 
of the NRD, and the carboxyl-terminal short region), suggest- 
ing that they may also be transcription activators. We demon- 
strated that B-Myb functions as a transcriptional activator [24], 
and identified the transcriptional activation domain containing 
a cluster of acidic amino acids [28]. In contrast to our observa- 
tion, other groups reported that B-Myb has no transcriptional 
activating capacity and functions as a repressor by competing 
with c-Myb for binding to DNA [11,42]. Our recent analyses 
to resolve this discrepancy indicate that B-Myb is a cell type- 
specific transcriptional activator (unpublished results). 
To understand the physiological role of A-Myb compared 
with c-Myb and B-Myb, we have investigated the tissue speci- 
ficity of A-myb expression and transcriptional activation by 
A-Myb. A-myb mRNA is mainly expressed in testis and periph- 
eral blood cells. Like c-Myb, but not B-Myb, A-Myb functions 
as a transcriptional activator in all cells examined, and its activ- 
ity is regulated by the NRD. 
2. Materials and methods 
2.1. Northern blotting 
The human tissue blots were purchased from Clontech (Palo Alto). 
As the A-myb-specific DNA probe, the 0.6-kb NdeI-Ncol DNA frag- 
ment (nucleotides 745-1315; nucleotide numbers are as in [31]) was 
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prepared from the human A-myb cDNA clone. The 2.0-kb NcoI-XbaI 
DNA fragment (nucleotides 113-2100; nucleotide numbers are as in 
[22]) prepared from the human c-myb cDNA clone was used to detect 
the c-myb RNA. Hybridization was done for 20 h at 42°C in the 
presence of 50% formamide 5 x SSPE, 2% SDS, 10 x Denhardt’s solu- 
tion, and 100 &ml of denatured salmon sperm DNA. The membranes 
were washed in 0.1 x SSC, 0.1% SDS at 50°C. 
2.2. Plasmid construction 
To isolate the cDNA clone encoding the C-terminal portion of the 
human A-Myb, which had been lacking in the previously characterized 
clones, the 3’ RACE (rapid amplification of cDNA ends) method was 
used as described by Frohman et al. [12]. Since analyses of the previ- 
ously isolated cDNA clone showed that it lacked a very short region 
encoding 7 amino acids, a synthetic oligonucleotide containing this 
portion was ligated to the previously isolated cDNA clone to generate 
the cDNA clone encoding the full-length A-Myb. The plasmid pact-A- 
myb expressing the full-length A-Myb was constructed by use of the 
A-myb cDNA and the plasmid containing the 5’ regulatory region of 
the chicken /I-cytoplasmic actin gene, as described in the case of pact- 
B-myb [24]. 
All plasmids designed to express mutant A-Myb proteins in cultured 
cells were generated from the plasmid pact-A-myb. A series of C- 
terminal truncated mutants of A-Myb were constructed by generating 
termination codons at the appropriate sites by oligonucleotide-directed 
mutagenesis as described by Kunkel et al. [21]. In mutants CT673, 
CT590, and CT296, an XbaI site that overlapped the termination codon 
was also generated. This caused a conversion of the Asn-673 in CT673 
and Ser-296 in CT296 to Cys and Be residues, respectively. Similarly, 
in CT396 and CT325, EcoRI and HpaI sites were generated, respec- 
tively. In CT325, Asp-325 was converted to a Gly residue. To make the 
A- 
(5 
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mutant ATA, lacking the region between amino acids 218 and 278, the 
NdeI-PvuII fragment was deleted from pact-A-myb and then self- 
ligated after generating a flush end with Klenow enzyme. 
2.3. DNA transfection, CAT assay, and RNase protection 
analysis 
Co-transfection experiments using African green monkey kidney 
cells (CV-I), mouse fibroblasts (NIH 3T3), or human epitheloid carci- 
noma cells (HeLa) and the CAT reporter plasmid pAlOCAT6MBS-I, 
were done as described [26]. All CAT co-transfection experiments were 
repeated three or four times, and typical results are shown. The differ- 
ence between each set of experiments were within 30%. The RNase 
protection analysis was done as described [24,27]. 
2.4. Western blot analysis of A-Myb mutants 
A mixture of 9 pg of the plasmid DNA to express A-Myb mutants 
and 0.1 fig of the internal control plasmid pact-/I-gal was transfected 
using the CaPO, method into 293T cells (derived from the adenovirus 
type 5-transformed human embryonic kidney 293 cell line) [7]. A-Myb 
proteins were detected as described by Western blotting with the rabbit 
polyclonal antibody aCT5 raised against the fusion protein (GST-CT5) 
containing glutathione S-transferase (GST) and the c-Myb DNA-bind- 
ing domain. 
2.5. Gel mobility shift assay by using lysates prepared from transfected 
cells 
The plasmid DNA to express various forms of A-Myb was trans- 
fected into 293T cells, and nuclear extracts (NE) were prepared 48 h 
after transfection as described by Dignam et al. [6]. The amount of 
A-Myb protein in NE was examined by Western blotting. The gel 
mobility shift assay was done as described [19]. 
Fig. 1. Tissue distribution of A-myb mRNA in human adult tissues. RNA filters were obtained from Clontech (Palo Alto, CA), and each lane contained 
2pg of poly(A)’ RNA. Northern blot analyses were done as described in section 2. The 5.0-kb A-myb mRNA and 3.4-kb c-myb mRNA are indicated 
by arrows. 
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3. Results 
3.1. Tissue distribution of A-myb mRNA 
To examine the pattern of expression of A-myb in various 
human tissues, we used the A-myb-specific DNA probe in 
Northern blot analysis. As shown in Fig. 1 5.0-kb A-myb 
mRNA was detected only in testis and peripheral blood leuko- 
cytes. The sequential hybridization of the same blots with the 
c-myb-specific probe indicated that c-myb has a distinct pattern 
of expression from A-myb (Fig. 1). The 3.4-kb c-myb mRNA is 
expressed at the highest level in thymus, at a moderate level in 
lung, small intestine, and colon, and at a low level in prostate, 
ovary, and peripheral blood leukocytes. Thus, the tissue specificity 
of expression is clearly different between A-myb and c-myb. 
3.2. Transcriptionul activation by A-Myb 
We had isolated and characterized the human A-myb cDNA 
clones, but they lacked the C-terminal portion of the A-Myb- 
coding region [31]. To analyze the function of A-Myb, it is 
necessary to isolate the cDNA clones encoding the full-length 
A-Myb. By using the 3’ RACE method, we have isolated a 
cDNA clone encoding the C-terminal region of A-Myb. Struc- 
ture analyses of this clone indicated that the full-length A-Myb 
contains 7 more amino acids (TSRALIL) in its C-terminal 
region than the previously reported protein [31]. Based on this 
finding, we have constructed an expression vector to express 
the full-length A-Myb. 
To examine whether A-Myb is also a transcriptional activa- 
tor like c-Myb, we did a co-transfection experiment with the 
A-myb expression plasmid pact-A-myb and the reporter plas- 
mid pAlOCAT6MBS-I (Fig. 2A). This reporter plasmid con- 
tains six tandem repeats of the MBS-I sequence, to which both 
c-Myb and B-Myb can specifically bind, linked to the SV40 
early promoter and the CAT gene. We have also confirmed that 
A-Myb can bind to the MBS-I sequence (see Fig. 5). We had 
reported that in a co-transfection assay with increasing 
amounts of effector plasmid, the c-Myb activity increases up 
to a maximum with about 0.75 pg of c-Myb expression plasmid, 
and then decreased with further increases in the amount of 
c-Myb [32] (also see Fig. 2A). This negative autoregulation is 
a consequence of c-Myb homodimer formation through the 
leucine zipper and the inability of the c-Myb homodimer to 
bind to DNA. In contrast, B-Myb activity is not autoregulated 
by a similar mechanism [28] (also see Fig. 2A). In CV-1 cells, 
the degree of transactivation by wild-type A-Myb increased up 
to a maximum 8-fold with 2 fig of A-Myb expression plasmid. 
After reaching this maximum, the degree of transactivation 
decreased with further increases in the amount of A-Myb. 
These results indicate that A-Myb can function as a transcrip- 
tional activator and also that A-Myb activity is negatively reg- 
ulated like c-Myb. 
To confirm that A-Myb activated transcriptional initiation, 
we did Sl nuclease mapping using the reporter plasmid 
pAlOMPG6MBS-I, in which the CAT gene of 
pAlOCAT6MBS-I was replaced by the mouse j?-globin gene 
(Fig. 2B). As expected, the protected DNA fragment of 18& 
190 nucleotides, which corresponds to the mouse/?-globin tran- 
scripts started at the correct site, was detected in transfections 
containing pact-A-myb, although the levels ofj%globin mRNA 
in transfections containing the control effector plasmid were 
almost undetectable. 
??A-Myb 
0 B-Myb 
s 
8 
.- 
iii 
.z 
P 6 
4 
2 
1 I I 1 
0 2 4 6 8 
Amount of effector plasmid (pg) 
Fig. 2. Transcriptional activation by A-Myb. (A) CAT co-transfection 
experiments. Mixtures of4pg ofthe reporter plasmid pAlOCAT6MBS- 
I DNA, varying amounts of the effector plasmid DNA to express 
A-Myb. B-Myb, or c-Myb, and 2 fig of the internal control plasmid 
pact-p-gal DNA were transfected into CV-I cells. The total amount of 
effector plasmid was adjusted to 8 pug by addition of varying amounts 
of pact-l DNA. CAT assays were done for 1.5 h. The degree of transac- 
tivation (compared with a sample without Myb expression plasmid) 
was measured and is shown. (B) RNase protection analysis. Mixtures 
of the reporter plasmid pAlOM/?G6MBS-I DNA (6 pup), the effector 
plasmid DNA (6 pg) to express A-Myb, B-Myb, c-Myb, or no protein 
(control), and the reference plasmid pRSV-MBG DNA (2 pug) were 
transfected into CV-1 cells, and RNA was prepared 40 h after transfec- 
tion. An RNase protection assay was done with 20 pg of total RNA. 
The protected fragments that correspond to transcripts initiated at the 
SV 40 early promoter in pAlOMbG6MBS-I and the RSV promoter in 
pRSV-M/IG are indicated by arrows 1 and 2, respectively. “P-Labeled 
pBR322 digested with Hid was used as a size marker. 
B-Myb stimulates the CAT expression from the reporter 
plasmid pAlOCAT6MBS-I in DV-1 and HeLa cells, but not in 
some other types of cells such as NIH 3T3 ([24], our unpub- 
lished results), indicating that B-Myb is a cell type-specific 
transcriptional activator. To examine whether A-Myb also 
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Fig. 3. Transactivation by A-Myb deletion mutants. (A) Structures of a series of deletion mutants. The three-fold tandem repeats in the DNA-binding 
domain (DBD) are indicated by the arrows. A closed box shows the region rich in acidic amino acids. The region conserved between three members 
of the myb gene family (CR) is indicated by the shaded box. (B) The results of CAT co-transfection experiments. CAT co-transfection experiments 
were done by using varying amounts of the effector plasmid DNA to express A-Myb mutant proteins indicated in each column as described in the 
legend to Fig. 2A. The degree of transactivation is shown. 
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does not have transactivating capacity in some types of cells like 
B-Myb, we used NIH 3T3 and HeLa cells for co-transfection 
experiments. A-Myb stimulated the CAT expression from the 
reporter plasmid pA 1 OCAT6MBS-I about 7- and 5-fold in NIH 
3T3 and HeLa cells, respectively (data not shown). We also 
confirmed that A-Myb also functions as a transcriptional acti- 
vator in 293T cells in which B-Myb does not have the transac- 
tivating capacity (data not shown). Thus, our results indicate 
that A-Myb is a transcriptional activator in all the types of cells 
examined, like c-Myb. 
3.3. Deletion analyses of A-Myb 
To analyze the functional domains of A-Myb, we first made 
a deletion mutant of the putative transcriptional activation 
domain (ATA), which is rich in acidic amino acids and located 
in the region downstream of the DNA-binding domain (Fig. 
3A). As expected, the dTA mutant did not stimulate the CAT 
expression from the pAlOCAT6MBSI reporter (Fig. 3B), indi- 
cating that this acidic region functions as a transcriptional 
activation domain. To examine whether A-Myb also has a 
regulatory domain like the NRD of c-Myb, a series of carboxyl- 
terminally truncated mutants was constructed (Fig. 3). To iden- 
tify the regulatory domain of A-Myb clearly, we measured 
transactivation by various forms of A-Myb with increasing 
amounts of A-Myb expression plasmid (Fig. 3B); we have ver- 
ified that this results in correspondingly varying amounts of 
protein in the transfected cells (data not shown). The transacti- 
vation by increasing amounts of two C-terminal mutants 
CT590 and CT678 were similar to that of wild-type, indicating 
that the C-terminal 152-amino acid region does not affect the 
A-Myb activity. Further truncation to amino acids 396 or 325 
changed the doseeresponse curve. The degree of transactiva- 
tion by CT396 or CT325 increased to a maximum I.5 to 17- 
fold, which is about 2-fold higher than the wild-type, with 
0.5 pg of A-Myb expression plasmid, and then turned off rap- 
idly with further increases in the amount of effector plasmid. 
These results suggest that the region between amino acids 396 
and 596 is the regulatory domain, deletion of which enhances 
the transactivation by low amounts of A-Myb but does not 
affect the negative regulation by increasing amounts of A-Myb. 
In contrast, the degree of transactivation by CT296 increased 
continuously with the amount of A-Myb expression plasmid. 
Thus, the degree of transactivation with 8 pg of the A-Myb 
expression plasmid was 1 &fold by CT296, but only 2.7-fold by 
CT325. These results indicate that the small region between 
amino acids 296 and 325 is essential for the negative regulation 
of A-Myb activity. Thus, two NRDs, amino acids 396-596 and 
2966325, were identified in A-Myb. 
To examine whether the expected size of proteins were pro- 
duced from each expression plasmid and whether the deletion 
mutations affected the protein stability, we analyzed the mutant 
proteins expressed in 293 T cells after DNA transfection (Fig. 
4). The wild-type and six mutant proteins were detected by 
Western blotting as the expected size of proteins by using the 
polyclonal antibody aCT5 raised against a fusion protein com- 
prising GST and the DNA-binding domain of c-Myb. All of 
these proteins were expressed at almost the same level, indicat- 
ing that these six mutant proteins also had similar stability. 
3.4. Negative regulation of‘ DNA-binding activity of A-My6 
To examine whether the DNA-binding activity of A-Myb is 
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Fig. 4. Immunodetection of A-Myb mutant proteins expressed in trans- 
fected cells. A mixture of 9 pg of DNA to express the A-Myb proteins 
indicated above each lane or no protein (control) and 0.1 fig of the 
internal control plasmid pact-/?-gal DNA were transfected into 293T 
cells. Proteins were prepared from transfected cells, separated by 10% 
SDS-PAGE, and then the proteins were detected by Western blotting 
with polyclonal antibody aCT5. Prestained molecular size markers 
(Bio-Rad) are indicated to the left. 
negatively regulated by a specific region, especially the NRDs 
described above, we did gel mobility shift experiments using NE 
that was prepared from 293T cells transfected by the expression 
plasmid encoding various forms of A-Myb (Fig. 5). The DNA 
binding of Myb was not detected by using NE prepared from 
transfected CV-1 or NIH 3T3 cells; probably the efficiency of 
transfection into these cell lines were low. The cell line 293T is 
more transfectable than these cells, and the DNA binding activ- 
ity of c-Myb can be easily detected by using NE prepared from 
the transfected 293T cells (our unpublished results). When we 
used NE prepared from 293T cells transfected by wild-type, 
CT678, or CT590 expression vectors, no specific retarded band 
corresponding to the A-Myb-DNA complex was detected. In 
contrast to this, NE containing CT396, CT325, or CT296 gen- 
erated specific retarded bands. To confirm that the generated 
band contains the A-Myb protein expressed from the trans- 
fected DNA, the Myb-specific antibodies were added to the 
binding reaction. Among three antibodies used, the monoclo- 
nal antibody MAbS-I, which can recognize both c-Myb and 
A-Myb, supershifted the retarded band, indicating that the 
observed retarded band was generated by A-Myb. These results 
indicate that the DNA-binding activity of A-Myb is negatively 
regulated by the region between amino acids 396 and 590, and 
that the removal of this region increases the DNA binding. 
These results are consistent with the results of CAT co-transfec- 
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Fig. 5. Negative regulation of the DNA-binding activity of A-Myb by the C-proximal portion. (A) Gel retardation analysis using NE prepared from 
293T cells transfected by A-Myb expression plasmid. 293T cells were transfected by the plasmid to express various forms of A-Myb shown above 
each lane, or no protein (control), and NE was prepared. The probe containing the Myb-binding site, MBS-I, was used for the binding reaction. 
In lanes indicated by +, a 100-fold molar excess unlabeled DNA competitor containing the MBS-I sequence was added. (B) Effects of the Myb-specific 
antibodies on the formation of the DNA-protein complex. The gel shift assays were done using the MBS-1 probe and NE that was prepared from 
293T cells transfected by A-Myb CT296 expression plasmid. The anti-c-Myb monoclonal antibodies (MAbl-1 and MAbS-l), polyclonal antibody 
raised against the DNA-binding domain of c-Myb (aCTS), rabbit normal serum (preimmune), purified rabbit IgG, lOO-fold molar excess unlabeled 
DNA competitor containing the MBS-1 sequence (MBS-l), or no competitor (-) were added to the binding reaction. 
tion experiments that the degree of transactivation by CT396 
is about 2-fold higher than wild type with a small amount of 
A-Myb expression plasmid. 
4. Discussion 
The c-myb mRNA was originally found to be expressed pre- 
dominantly in immature hematopoietic cells. However, it was 
reported that more tissues and cells expressed the c-myb mRNA 
as shown in Fig. 1 [40]. The cell type and tissue specificity of 
expression of the B-myb mRNA is broader than that of c-myb 
(our unpublished results). Compared with c-myb and B-myb, 
the tissue specificity of A-myb expression is narrow and re- 
stricted to testis and peripheral blood leukocytes (Fig. 1). The 
expression of A-myb mRNA in testis was also reported in 
Xenopus and mouse [3,23,37]. The Xenopus and mouse A-myb 
expression is observed through the early stages of sperm devel- 
opment during the proliferation of spermatogonial cells, and 
then down-regulated as the primary spermatocytes meiotically 
divide [23,37]. Such expression has strong parallels with c-myb 
expression in immature haematopoietic lineages. However, in 
contrast to c-myb and B-myb, human A-myb is expressed in 
resting T lymphocytes, and its levels gradually decrease after 
mitogenic stimulation [14]. Thus, expression of A-myb in testis, 
but not in T lymphocytes, appears to correlate with prolifera- 
tion. To clarify the physiological role of A-Myb, it is important 
to clarify the relationship between A-myb expression and cellu- 
lar proliferation. 
Our analyses indicate that A-Myb functions as a transcrip- 
tional activator in all the cells examined. During preparation 
of this manuscript, two other groups also reported that A-Myb 
is a transcriptional activator [10,15]. This characteristic is the 
same as c-Myb, but different from B-Myb, which is a cell 
type-specific transcriptional activator. The structures of func- 
tional domains of A-Myb, B-Myb, and c-Myb are shown in 
Fig. 6 and compared to each other. The structure of functional 
domain in A-Myb is very similar to c-Myb: DNA-binding do- 
main, transcriptional activation domain, and negative regula- 
tory domain from the N-terminus. In addition to the DNA- 
binding domain, the amino acid sequence in the transcriptional 
activation domain, especially the acidic region between amino 
acids 259 and 281 of A-Myb, is highly conserved between c- 
Myb and A-Myb. In contrast, the amino acid sequence in the 
corresponding region of B-Myb does not have significant ho- 
mology with c-Myb and A-Myb. This difference may explain 
why A-Myb and c-Myb are transcriptional activators in all cells 
examined, but B-Myb is a cell type-specific transcriptional acti- 
vator. 
The results of our deletion analyses using a series of A-Myb 
deletion mutants indicate the presence of two NRDs in A-Myb: 
amino acids 396-590 and 296-325. The full-length form of 
A-Myb exhibited no DNA-binding activity in our gel mobility 
shift assay, but a deletion of the C-proximal region (amino acids 
396-590) increased the DNA-binding capacity (Fig. 5A). Simi- 
lar observations were also reported for several other DNA- 
binding proteins such as Ets. This probably causes an increase 
in transactivating capacity at low amounts of A-Myb. This 
C-proximal NRD contains the region conserved in the myb 
gene family. We have found that the conserved region in c-Myb 
negatively regulates its DNA-binding activity (our unpublished 
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Fig. 6. Functional domains identified in A-Myb. Comparison of func- 
tional domains between three members of the myb gene family. The 
three tandem repeats in the DNA-binding domain (DBD) is shown by 
arrows. The closed box indicates the region that is rich in acidic amino 
acids. Two regions conserved between three members (CR) are indi- 
cated by shaded boxes. DBD, DNA-binding domain; TAD, transcrip- 
tional activation domain; NRD, negative regulatory domain; LZ, leuc- 
ine zipper structure. Percentages indicate percent identity in each en- 
compassed by dashed lines between human A-Myb and human c-Myb, 
or between human B-Myb and human c-Myb. 
results). Deletion of this conserved region of c-Myb results in 
oncogenic activation of c-myh, and v-Myb carried by AMV 
lacks this region [ 171, suggesting that the corresponding region 
in A-Myb also has biological importance. 
The transactivating capacity of A-Myb is also negatively 
regulated through the small region between amino acids 296 
and 325. In co-transfection assays, maximal Myb-induced 
transactivation occurs with low amounts of wild-type A-Myb, 
while higher levels of A-Myb result in reduced A-Myb-induced 
transactivation. This negative regulation is impaired by a dele- 
tion of the region between amino acids 297 and 325. These 
observations are very similar to those obtained by c-Myb. 
c-Myb activity is also negatively regulated, and a disruption of 
the leucine zipper structure completely eliminated this regula- 
tion [32]. This negative regulation is due to the formation of the 
c-Myb homodimer through the leucine zipper and the inability 
of the dimer to bind to DNA, indicating that c-Myb itself can 
function as an inhibitor of c-Myb. Recently, we found that 
co-expression of the catalytic subunit of CAMP-dependent pro- 
tein kinase (PKA) or the activated src gene product (Src) abro- 
gates this negative regulation of c-Myb activity (our unpub- 
lished results). These results suggest that the specific growth 
signals that are transduced via PKA and Src, stimulates c-Myb 
activity through blocking the association of c-Myb with an 
inhibitor. The mechanism of negative regulation of A-Myb 
activity is unclear, but this may be important for the regulation 
of A-Myb activity by specific growth signals like in the case of 
c-Myb. The small region between amino acids 297 and 325 of 
A-Myb is predicted to form an amphipathic a-helix and con- 
tains characteristic hydrophobic residues at every seventh posi- 
tion (leucine zipper-like motif). However, disruption of this 
leucine zipper-like motif by introducing point mutations did 
not abolish the negative regulation of A-Myb activity. Another 
type of structure in this region may be important for the nega- 
tive regulation of A-Myb activity. 
It should be noted that the amino acid sequence of the leucine 
zipper-containing region of c-Myb (amino acid 375403) is 
significantly conserved in A-Myb (amino acids 341-369) which 
is located further downstream from the leucine zipper-like 
motif described above: IO residues out of 29 amino acids are 
identical and 7 residues are similar. Although this region con- 
tains the putative leucine zipper motif. one proline residue is in 
this region, and a deletion of this region did not increase the 
transactivating capacity (our unpublished results). In addition, 
the corresponding region in Xenopus A-Myb contains three 
prolines, in spite of the highly conserved amino acid sequence 
between human A-Myb and Xenopus A-Myb in the whole pro- 
tein-coding region. These results suggest that the amino acid 
sequence of the leucine zipper-containing region in c-Myb is 
considerably conserved in A-Myb, but its ability to bind to the 
inhibitor(s) was lost during evolution. Instead of this region, 
another region (amino acids 297-325) in A-Myb could obtain 
the capacity to interact with inhibitor(s), although this region 
does not have completely similar characteristics to the canoni- 
cal leucine zipper motif. 
Further analyses of the mechanism of negative regulation of 
A-Myb activity, and the identification of target genes in testis 
and peripheral blood leukocytes, the transcription of which is 
activated by A-Myb, will be important to understand the phys- 
iological role of A-Myb. 
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